603305-89-1

Basic information

• Product Name: 7-BroMo-thieno[3,2-b]pyridine
• Synonyms: 7-BroMo-thieno[3,2-b]pyridine
• CAS NO: 603305-89-1
• Molecular Formula: C₇H₄BrNS
• Molecular Weight: 214.08236
• Mol File: 603305-89-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 299.8±20.0 °C(Predicted)
• Appearance: /
• Density: 1.748±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.07±0.30(Predicted)
• CAS DataBase Reference: 7-BroMo-thieno[3,2-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BroMo-thieno[3,2-b]pyridine(603305-89-1)
• EPA Substance Registry System: 7-BroMo-thieno[3,2-b]pyridine(603305-89-1)

Safety Data

• Hazardous Substances Data: 603305-89-1(Hazardous Substances Data)

Usage

General Description

7-Bromo-thieno[3,2-b]pyridine is a chemical compound with the molecular formula C7H4BrNS. 7-BroMo-thieno[3,2-b]pyridine is a thienopyridine derivative, which is commonly used in pharmaceutical research and organic synthesis. It is a heterocyclic compound that contains a bromine atom and a thieno ring fused to a pyridine ring. 7-Bromo-thieno[3,2-b]pyridine has potential biological activity and is often used as a building block for the synthesis of various pharmaceuticals and agrochemicals. It is also a useful reagent in organic chemistry for the construction of complex molecules. Its unique structure and properties make it a valuable compound in drug discovery and chemical synthesis.

Upstream product

• 69627-02-7 thieno[3,2-b]pyridin-7-ol 

Downstream Products

• 94191-12-5 3-bromothieno<3,2-b>pyridine 
• 1229624-38-7 C₁₉H₂₅N₃O₄S 

Relevant articles and documents

New di(hetero)arylethers and di(hetero)arylamines in the thieno[3,2-b]pyridine series: Synthesis, growth inhibitory activity on human tumor cell lines and non-tumor cells, effects on cell cycle and on programmed cell death

New fluorinated and methoxylated di(hetero)arylethers and di(hetero)arylamines were prepared functionalizing the 7-position of the thieno[3,2-b]pyridine, using copper (C-O) or palladium (C-N) catalyzed couplings, respectively, of the 7-bromothieno[3,2-b]pyridine, also prepared, with ortho, meta and para fluoro or methoxy phenols and anilines. The compounds obtained were evaluated for their growth inhibitory activity on the human tumor cell lines MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), HCT15 (colon carcinoma), HepG2 (hepatocellular carcinoma) and HeLa (cervical carcinoma). The most active compounds, a di(hetero)arylether with a methoxy group in the meta position relative to the ether function and two di(hetero)arylamines with a methoxy group either in the ortho or in the meta position relative to the NH, were further tested at their GI50 concentrations on NCI-H460 cells causing pronounced alterations in the cell cycle profile and a strong and significant increase in the programmed death of these cells. The fluorinated and the other methoxylated compounds did not show important activity, presenting high GI50 values in all the cell lines tested. Furthermore, the hepatotoxicity of the compounds was assessed using porcine liver primary cells (PLP2), established by some of us. Results showed that one of the most active compounds was not toxic to the non-tumor cells at their GI50 concentrations showing to be the most promising as antitumoral.

EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.